Cytosorbents (CTSO) Expected to Announce Earnings on Monday

Cytosorbents (NASDAQ:CTSO - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Monday, March 31st. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Cytosorbents Price Performance

Shares of CTSO stock traded down $0.02 on Thursday, hitting $1.00. 64,202 shares of the stock traded hands, compared to its average volume of 145,101. The firm has a market cap of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a 50 day simple moving average of $1.07 and a two-hundred day simple moving average of $1.05. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61.

Analysts Set New Price Targets

Several analysts recently issued reports on CTSO shares. StockNews.com started coverage on Cytosorbents in a research report on Wednesday. They set a "hold" rating for the company. D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Remove Ads

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.